banner image

Events & Presentations

Events & Presentations

Upcoming Events

There are no upcoming events scheduled at this time.

Past Events

Corporate Presentation

Presentations

64th American Society of Hematology (ASH) Annual Meeting and Exposition
December 12, 2022
Preliminary Results of a Phase-2 Clinical Trial of the ALK-2 Inhibitor KER-047 for Treatment of Iron-Refractory Iron Deficiency Anemia 2.3 MB
ALK2 Inhibition and a Modified Activin Receptor Type IIA Ligand Trap Cotherapy Maximized Hematologic Improvements in a Mouse Model of Anemia of Inflammation 451.3 KB
Effects of KER-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes 3.3 MB
Modulation of TGF-β Superfamily Signaling to Treat Myelofibrosis and Mitigate JAK Inhibitor Toxicity: A Report on the Phase 2 Study of KER-050 in Participants with Myelofibrosis 1.4 MB
RKER-050, a Novel Activin Receptor Type II Ligand Trap, Rescued Anemia and Reduced Bone Loss in a Mouse Model of Myelodysplastic Syndromes 1.3 MB
63rd American Society of Hematology (ASH) Annual Meeting and Exposition
December 13, 2021
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes 1.5 MB
RKER-050 Rescued Ruxolinitib (Rux)-induced Reduction in Red Blood Cell Parameters 413.7 KB
KER-050, an Inhibitor of TGF-β Superfamily Signaling, Promoted Thrombopoiesis and Reversed Immune Thrombocytopenia in Mouse Model of Disease 666.5 KB
A Monoclonal Antibody Targeting ALK2 as a Potential Therapeutic Agent for Anemia of Inflammation 448.3 KB
EHA2021 Virtual Congress
June 11, 2021
62nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 7, 2020
25th European Hematology Association (EHA) Congress (2020)
June 12, 2020
Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets 1.3 MB
Poster Presentation: Administration of KER-050, a Novel ActRIIA Ligand Trap, to Healthy Participants Elicited Robust and Sustained Increases in Hemoglobin and Platelets (Updated as of April 2021) 1.4 MB
Poster Presentation: KER-050, a Novel Modified ActRIIA Ligand Trap, Increases Red Blood Cell Production in Cynomolgus Monkeys 1.3 MB
Poster Presentation: KER-050, a Novel Inhibitor of TGF-β Superfamily Signaling, Induces Red Blood Cell Production and is a Potential Candidate for the Treatment of Ineffective Erythropoiesis 1.1 MB
Oral Presentation: Selective Inhibition of ALK2 Signaling Ameliorates Disease in a Novel Model of Iron Refractory Iron Deficiency Anemia (IRIDA) 2.5 MB
Follicular_Lymphoma_in_Bone_Marrow image